The National Ataxia Foundation (NAF) is an organization devoted to raising awareness, supporting families, and funding research for Ataxia, a rare and progressive neurological condition that impairs ...
Phase 2b POLAR study, a global, randomized, double-blind, placebo-controlled clinical trial evaluating GLM101 for the ...
Clinical Trials Arena on MSN
Glycomine concludes Phase IIb POLAR study enrolment
The trial has dosed 43 children and adults aged four to 47 years with PMM2-CDG.
CHICAGO (WLS) -- The Friedrich's Ataxia Research Alliance (FARA) invites families, cyclists, and everyone else to their 5th Annual rideATAXIA Chicago event on July 24, 2016. The multi-route cycling ...
RICHFIELD, Wis. (CBS 58) -- The 4th Annual National Ataxia Bowl for a Cure will take place Sunday, Sept. 28 at Pioneer Bowl in Richfield from 11 a.m. to 4 p.m. The fundraiser supports research, ...
Ataxia is a degenerative disease of the nervous system. Symptoms include slurred speech, stumbling, falling and incoordination. Find out what the National Ataxia Foundation is doing to fund research.
The Gehr family has always had a love and a talent for the performing arts. “I really lived a pretty unaffected life until about third grade,” said 25-year-old Michael Gehr. As a kid, Michael was what ...
The FDA has granted orphan drug designation to Cure Rare Disease’s CRD-002, an antisense oligonucleotide therapeutic for the treatment of spinocerebellar ataxia (SCA), including spinocerebellar ataxia ...
The National Ataxia Foundation (NAF) is an organization devoted to raising awareness, supporting families, and funding research for Ataxia, a rare and progressive neurological condition that impairs ...
POLAR is a randomized, double-blind, placebo-controlled study that enrolled 43 patients with PMM2-CDG across 15 sites globally with topline data expected in the fourth quarter of 2026 Primary endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results